Cobalis Corp.

Dr. Yakatan served from 1998 through 2005 as President and Chief Executive Officer for Avanir Pharmaceuticals of San Diego, CA (AMEX: AVN-R). Dr. Yakatan successfully directed the company's development and marketing of novel therapeutic products for the treatment of chronic diseases, including the NDA submission of Neurodex and the clinical program and regulatory strategy that led to the FDA approval of Abreva , the largest-selling OTC treatment for cold sores. Dr. Yakatan led the licensing effort for Abreva that resulted in a partnership with GlaxoSmithKline, as well as partnerships with Novartis and AstraZeneca. In addition, Dr. Yakatan has extensive experience with compounds that inhibit the production of IgE (Immunoglobulin epsilon) antibodies, a key

Dr. Brodsky is a celebrated Naturopathic Doctor, nationwide lecturer on Natural Medicine, and consultant to major pharmaceutical companies. As well as owning his own pharmacy, he has also been on the teaching staff of The University of Southern California School of Pharmacy and the University of the Pacific Pharmacology Department. He has published multiple articles in major national medical journals.

Mr. Pickard has served as a financial consultant to Cobalis since late 2004. He has practiced as a CPA for over 19 years, and has been involved in

Education: University of Colorado School of Medicine, M.D., Internship: Good Samaritan Hospital - General Rotating Internship, Pediatric Residency: St. Joseph's Hospital, University of Colorado Medical Center, University of Colorado Medical Center - Chief Resident in Pediatrics.

Mr. Kay has served as a director and Chief Executive Officer of the Company since September 2007. From October 2004 to September 2007, Mr. Kay provided executive consulting services to several early stage companies, mainly in the San Francisco Bay and San Diego areas. During that time he also served as an executive advisor and interim Chief Executive Officer to the U.S. healthcare/life sciences venture capital fund, Kleiner Perkins Caufield and Byers. From January 2001 through October 2004, Mr. Kay was the President, Chief Executive Officer and a director of Quidel Corporation, a leading company in the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the POC in infectious diseases and reproductive health. During his tenure he designed and managed a strategy responsible for building and sustaining market leadership of rapid influenza testing. Mr. Kay received his Masters degree in Business Administration in 1982 from Pepperdine University and his Bachelor of Business Administration degree from the University of San Francisco.